Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Quarterly Report · 10-Q

Niagen Bioscience, Inc.

NAGENASDAQEQUITYCurrent

Quarterly Report

Filed Aug 4, 2026Accepted Aug 4, 2026, 4:04 PM EDTCIK 1386570Accession 0001386570-26-000043
Share

Company context

Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly ChromaDex Corp., is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality.

Current securities

Historical securities (1)

Recent company filings

  1. Results of Operations and Financial Condition · Regulation FD DisclosureAug 4, 2026
  2. 424B5 filingJul 10, 2026
  3. EFFECT filingJul 9, 2026
  4. Submission of Matters to a Vote of Security HoldersJun 29, 2026
  5. S-3 filingJun 29, 2026

As-filed source

Primary evidence